Efficacy and Safety of Long-Term (6 Months) Innohep® Treatment Versus Anticoagulation with a Vitamin K Antagonist (Warfarin) for the Treatment of Acute Venous Thromboembolism in Cancer Patients / IN 0901 INT - DVT study.

Trial Profile

Efficacy and Safety of Long-Term (6 Months) Innohep® Treatment Versus Anticoagulation with a Vitamin K Antagonist (Warfarin) for the Treatment of Acute Venous Thromboembolism in Cancer Patients / IN 0901 INT - DVT study.

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Tinzaparin sodium (Primary) ; Warfarin
  • Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism; Venous thromboembolism
  • Focus Therapeutic Use
  • Acronyms CATCH; DVT
  • Sponsors LEO Pharma
  • Most Recent Events

    • 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress
    • 19 Aug 2016 Primary endpoint has not been met. (Composite end-point represented by the time in days from randomisation to the first occurrence of VTE), as reported by LEA Pharma Media Release.
    • 18 Aug 2015 Results published in the JAMA: the Journal of the American Medical Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top